Meet The Team 
Leadership That Inspires
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem arcu amet tristique turpis purus, in. Feugiat dictumst eget sem rutrum sem. Vitae, vestibulum vel hendrerit massa duis vehicula et, vulputate.
Franklin Charles
Director of Marketing
Franklin Charles
Director of Marketing
Resources
egnite Introduces Customer Access to Its National Cardiovascular Registry and Launches 2026 Call for Science Investigator-Initiated Study Program
egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.
Cath Lab Capacity is Up—But Structural Heart Procedures Are Being Outpaced by Other Interventions
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
From Black Box to Breakthrough: Unlocking Hidden Care Patterns with LLM-Enriched Data
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.